Cogent Biosciences-Blueprint Medicines tiff turns spicy on eve of study readout

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

This story is an excerpt from Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

Cogent Biosciences and Blueprint Medicines are direct competitors who hate each other. 

During a talk at the recent Jefferies Global Healthcare Conference, Cogent CEO Andy Robbins said Blueprint Medicines’ Ayvakit was so toxic that it was killing patients. Only after Blueprint lowered the Ayvakit dose was the drug tolerable enough to be modestly effective.